At the 2024 NYC Neuromodulation Conference, Magnus Medical presented new clinical data on the effectiveness of their SAINT therapy. This new neuromodulation treatment, which is a core area of partnership with Kaizen Brain Center, holds a new promise for patients with treatment-resistant depression.
Based on these clinical findings, patients receiving SAINT therapy can expect to rapidly achieve remission and maintain remission over a long period of time by receiving ongoing support and additional treatments.
Check out how SAINT® therapy achieves 12 months of sustained remission from depression through personalized continuation treatment.
What is SAINT Therapy?
SAINT therapy is an FDA-approved treatment that uses MRI-guided transcranial magnetic stimulation (TMS) to stimulate the specific regions of the brain that require treatment. The therapy’s recent study showed that the patient could be free from depression for up to one year, which is a major breakthrough in the field of individualized mental health treatment.
SAINT therapy has already been highly effective with helping numerous patients achieve relief from treatment-resistant depression and their stories are a beacon of hope for others.
To learn more about Magnus Medical’s SAINT therapy and the company’s continued collaboration with Kaizen Brain Center, contact us at Kaizen Brain Center and Magnus Medical .